PERSONAL INFORMATION

Family name, First name: de Miranda, Noel F.C.C. Researcher unique identifier(s): 0000-0001-6122-1024 (ORCID) URL for web site: https://demirandalab.com/

SYNOPSE OF RESEARCH ACTIVITIES:

I am the PI of the Cancer Immunogenomics group at the Leiden University Medical Center. My group combines the use of high-end genomic, transcriptomic, and proteomic technologies for the study of cancer genetics and immunology. The main aim of the group is to support the development of novel therapies to enrich the immunotherapy toolbox for the treatment of advanced cancers. The group's activities are subdivided into two major pillars: 1) the discovery of immunotherapeutic targets in cancer patients that are not amenable to state-of-the-art immunotherapies and 2) the identification of (innate) immune cell subsets with immunotherapeutic potential.

CURRENT POSITION

2020 -	Associate Professor Department of Pathology, Leiden University Medical Center, The Netherlands.
2017 - 2020	Assistant Professor Department of Pathology, Leiden University Medical Center, The Netherlands.
2016 -	Principal Investigator and Head of the ImmunoGenomics research group Department of Pathology, Leiden University Medical Center, The Netherlands.
PREVIOUS I	POSITIONS
2018	Visiting Researcher at Prof.dr. Zlatko Trajanoski's Lab. Division of Bioinformatics, Medical University of Innsbruck, Austria.
2014 - 2015	Postdoctoral Researcher Department of Pathology, Leiden University Medical Center, The Netherlands.
2010 - 2013	Postdoctoral Researcher Division of Clinical Immunology, Karolinska Institutet, Sweden.
2006 - 2010	PhD fellow Department of Pathology, Leiden University Medical Center, The Netherlands.
FELLOWSH 2022 -	IPS AND AWARDS VIDI award, Netherlands Organization for Scientific Research (800.000€).
2020 -	LUMC C.J. Kok Prize
2019 -	European Research Council Starting Grant (1.500.000€)
2016 -	VENI award, Netherlands Organization for Scientific Research (250.000€).
2015 -	Bas Mulder/Young Investigator Award, Alpe d'HuZes/Dutch Cancer Society (420.000€).
2015 -	Fellowship in Young Onset, Late-Stage Colorectal Cancer Research attributed by the American Association for Cancer Research, Michael's Mission, and Fight Colorectal Cancer patient advocates (92.000€).
SUPERVISIC	ON OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS
2015 -	3 Postdocs: Dr. Dina Ruano, Dr. Joana Brás Gomes Nunes, Dr. Jessica Roelands.

11 PhD students: <u>Main supervisor</u> of Marieke Ijsselsteijn, Thomas Brouwer, Jitske van den Bulk, Ricki Krog, Li Zheng. <u>Co-supervisor</u> of Stephanie Schubert, Natasja de Vries, Helena Ferreira, Mariana Silva, Ana Teixeira, and Sara Cardoso. HF, MS, and AT are affiliated to I3S - Institute of Health Innovation and Research, University of Porto, Portugal. SC is affiliated to University of Minho, Portugal.

2011-2013 1 Postdoc: Dr. Chenglin Wu (currently postdoctoral research at Stockholm

University, Stockholm, Sweden).

1 PhD student: Co-supervisor of Dr. Konstantinos Georgiou (currently Postdoctoral researcher at UCSF, San Francisco, USA).

LIST OF RELEVANT MEMBERSHIPS

- 2022 member of the Young Academy of the Royal Netherlands Academy of Arts and Sciences
- 2020 member of Young Academy Europe.
- 2020 member of the medical advisory board of Fight Colorectal Cancer
- 2019 member of Young Academy Leiden
- 2017 member of European Association for Cancer Research.
- 2016 member of LUMC's Young Faculty Network
- 2016 member of the Dutch Association for Gastroenterology
- 2014 member of American Association for Cancer Research

COMMISSIONS OF TRUST

- 2023 Editorial board member at Genome Medicine.
- 2020 2023 Academic Editor for Cancers.
- 2018 2020 Academic Editor for PLOS One.
- 2015 Reviewer of grant proposals for European Research Council, Dutch Cancer Society, French National Cancer Institute, among others.
- 2014 Reviewer for Nature Cancer, Nature Communications, Science Translational Medicine, Cancer Discovery, Cell Reports, among others

SELECTED RECENT WORKS

1. de Vries NL*, van de Haar J*, Veninga V*, Chalabi M*, Ijsselsteijn ME, van der Ploeg M, van den Bulk J, Ruano D, Haanen JB, Schumacher TN, Wessels LFA, Koning F#, **de Miranda NF#**, Voest E#. $\gamma\delta$ T cells are effectors of immunotherapy in cancers with HLA class I defects. *Nature* 2023.

2. Roelands J, van der Ploeg M, Dang H, Boonstra JJ, Hardwick JCH, Hawinkels LJAC, Morreau H, **de Miranda NF**. Transcriptomic and immunophenotypic profiling reveals molecular and immunological hallmarks of colorectal cancer tumourigenesis. *Gut* 2022.

3. Brouwer TP*, de Vries NL*, Abdelaal T, Krog RT, Li Z, Ruano D, Fariña A, Lelieveldt BPF, Morreau H, Bonsing BA, Vahrmeijer AL, Koning F, **de Miranda NFCC**. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry. *J Immunother Cancer* 2022.

4. de Vries NL, van Unen V, Ijsselsteijn ME, Abdelaal T, van der Breggen R, Farina Sarasqueta A, Mahfouz A, Peeters KCMJ, Höllt T, Lelieveldt BPF, Koning F, **de Miranda NF**. High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity. *Gut* 2020.

5. van den Bulk J, Verdegaal EME, Ruano D, Ijsselsteijn ME, Visser M, van der Breggen R, Duhen T, van der Ploeg M, de Vries NL, Oosting J, Peeters KCMJ, Weinberg AD, Farina-Sarasqueta A, van der Burg SH, **de Miranda NF**. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4. *Genome Med*. 2019.

*/# - equal contribution.

Other works: Google Scholar